New data confirms Novartis drug Afinitor® significantly extends time women with advanced breast cancer live without tumor growth
Updated results of a Phase III study...
8 December 2011 | By Novartis
Updated results of a Phase III study...
List view / Grid view
Updated results of a Phase III study...
8 December 2011 | By Novartis
Updated results of a Phase III study...
Novartis will showcase more than 160 presentations on data from…
2 December 2011 | By Novartis
Novartis will showcase more than 160 presentations on data from its robust oncology portfolio...
Afinitor® more than doubled the time women lived without tumor…
26 September 2011 | By Novartis
Afinitor® more than doubled the time women lived without tumor growth...
A Phase III study of Afinitor® (everolimus) tablets* met its…
23 September 2011 | By Novartis
A Phase III study of Afinitor® (everolimus) tablets* met its primary endpoint of best overall angiomyolipoma response rate...
The European Commission has approved Votubia® (everolimus) tablets* for the…
8 September 2011 | By Novartis
The European Commission has approved Votubia® (everolimus) tablets* for the treatment of patients aged 3 years and older...
The European Commission has approved Afinitor® (everolimus) tablets...
5 September 2011 | By Novartis
The European Commission has approved Afinitor® (everolimus) tablets...
The Committee for Medicinal Products for Human Use of the…
22 July 2011 | By Novartis
The Committee for Medicinal Products for Human Use of the EMA adopted a positive opinion for Afinitor® (everolimus) tablets...
Novartis announced Phase III trial results...
8 July 2011 | By Novartis
Novartis announced Phase III trial results...
Novartis announced today that the FDA approved Afinitor® (everolimus) tablets…
5 May 2011 | By Novartis
Novartis announced today that the FDA approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET)...
Novartis announced that the FDA Oncologic Drugs Advisory Committee recommended…
12 April 2011 | By Novartis
Novartis announced that the FDA Oncologic Drugs Advisory Committee recommended approval of Afinitor® (everolimus) tablets...
with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)...
6 December 2010 | By Novartis
with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)...